Visit COVID-19 resources

[Skip to Content]

Clinical Guidance

Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly

May 01

College Statement This statement refers only to injections of anti –Vascular Endothelial Growth Factor (anti-VEGF) medicines administered intra-ocularly directly through the conjunctiva and sclera using a sharp needle. This statement is the current College position and supersedes older statements on intraocular injections in the ARMD Guidelines for Management (2009) and Maximising Capacity in AMD Services

  • 1 May 2013

NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO

Mar 07

College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced

  • 7 March 2013

Updated guidance on Emergency Eye Care

Mar 05

An eye condition is an emergency if its occurrence is unpredictable and it requires treatment or admission at short notice to avoid damage to the eye or eyesight. The College will not attempt to identify every type of case that falls into the emergency category: it is the responsibility of the consultant under whose care

  • 5 March 2013